The estimated Net Worth of Ahmed Zaki Sabet is at least $210 mil dollars as of 3 January 2023. Mr Sabet owns over 750 units of Precipio Inc stock worth over $41,247 and over the last 5 years he sold PRPO stock worth over $0. In addition, he makes $168,794 as Chief Operating Officer at Precipio Inc.
Mr has made over 11 trades of the Precipio Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 750 units of PRPO stock worth $450 on 3 January 2023.
The largest trade he's ever made was buying 750 units of Precipio Inc stock on 3 January 2023 worth over $450. On average, Mr trades about 279 units every 103 days since 2019. As of 3 January 2023 he still owns at least 6,863 units of Precipio Inc stock.
You can see the complete history of Mr Sabet stock trades at the bottom of the page.
Ahmed Zaki Sabet is the Chief Operating Officer at Precipio Inc.
As the Chief Operating Officer of Precipio Inc, the total compensation of Mr Sabet at Precipio Inc is $168,794. There are 3 executives at Precipio Inc getting paid more, with Ilan Danieli having the highest compensation of $334,892.
Mr Sabet is 34, he's been the Chief Operating Officer of Precipio Inc since . There are 8 older and no younger executives at Precipio Inc. The oldest executive at Precipio Inc is Richard Sandberg, 77, who is the Director.
Ahmed's mailing address filed with the SEC is C/O PRECIPIO, INC., 4 SCIENCE PARK, NEW HAVEN, CT, 06511.
Over the last 7 years, insiders at Precipio Inc have traded over $449,545 worth of Precipio Inc stock and bought 88,796 units worth $87,860 . The most active insiders traders include Randal J Kirk, Ronald Asbury Andrews y Richard A Sandberg. On average, Precipio Inc executives and independent directors trade stock every 54 days with the average trade being worth of $44,781. The most recent stock trade was executed by Richard A Sandberg on 20 January 2023, trading 20,000 units of PRPO stock currently worth $15,600.
precipio is a cancer diagnostics reference laboratory, delivering the latest in advanced diagnostics and personalized medicine. our goal is to assist oncologists in providing the best care for their patients. at the intersection of academia, cancer research, and diagnostics, we connect physicians with world-renown pathologists at the yale school of medicine. at precipio, our customers and their patients benefit from the most accurate, expert diagnosis. we provide our customers exclusive access to some of the most innovative tests in the field of molecular diagnostics, developed through cutting edge research, and the ongoing pursuit and refinement of the science of personalized medicine.
Precipio Inc executives and other stock owners filed with the SEC include: